Beyond ocrelizumab in primary progressive multiple sclerosis

被引：0

作者：

Williams, Thomas ^{[1
]}

Chataway, Jeremy ^{[1
,2
]}

机构：

[1] UCL, Fac Brain Sci, UCL Queen Sq Inst Neurol, Queen Sq Multiple Sclerosis Ctr,Dept Neuroinflamm, London, England

[2] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England

来源：

NATURE REVIEWS NEUROLOGY | 2022年 / 18卷 / 11期

基金：

英国医学研究理事会;

关键词：

THERAPY;

D O I：

10.1038/s41582-022-00724-8

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Currently, the anti-CD20 monoclonal antibody ocrelizumab is the only approved treatment for primary progressive multiple sclerosis (PPMS). However, a new study suggests that other immunomodulatory disease-modifying therapies that are often used to treat relapsing forms of multiple sclerosis could be effective in people with PPMS who have evidence of active inflammatory disease.

引用

页码：641 / 642

页数：2

共 50 条

[41] Reduction of intrathecal immunoglobulin levels with ocrelizumab treatment in relapsing and primary progressive multiple sclerosis
Weber, Martin
Gelfand, Jeffrey
Bar-Or, Amit
Cameron, Briana
Ramesh, Akshaya
Anania, Veronica
von Budingen, H. -Christian
Herman, Ann
Spiciarich, David
Grondey, Katja
Schuetz, Konstantin
Winger, Ryan
Jia, Xiaoming
Harp, Christopher
Cross, Anne
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 570 - 571
[42] Hepatitis B reactivation in a patient with primary progressive multiple sclerosis under ocrelizumab treatment
Ciardi, M. R.
Iannetta, M.
Zingaropoli, M. A.
Pontecorvo, S.
Annecca, R.
Di Folco, M.
Mastroianni, C. M.
Vullo, V.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 944 - 945
[43] Evaluation of Ocrelizumab in Older Progressive Multiple Sclerosis Patients
Epstein, S.
Fong, K. T.
Levine, L.
De Jager, P. L.
Riley, C. S.
Vargas, W. S.
Farber, R.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 50 - 51
[44] Long-term ocrelizumab in progressive multiple sclerosis
Rose, Deja R.
Cohen, Jeffrey A.
LANCET NEUROLOGY, 2020, 19 (12): : 966 - 968
[45] Ocrelizumab in Highly Disabled Progressive Multiple Sclerosis Patients
Howard, D.
Healy, B. C.
Houtchens, M.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 201 - 201
[46] Ocrelizumab in highly disabled progressive multiple sclerosis patients
Houtchens, Maria
Howard, Danielle
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 82
[47] Evaluation of ocrelizumab in older progressive multiple sclerosis patients
Epstein, Samantha
Fong, Kathryn T.
De Jager, Philip L.
Levine, Libby
Riley, Claire
Wesley, Sarah
Vargas, Wendy S.
Farber, Rebecca
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 55
[48] Phase III Study of Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis: ORATORIO Study Design
Montalban, Xavier
Wolinsky, Jerry
Yin, Ming
Leppert, David
Glanzman, Robert
Chin, Peter
NEUROLOGY, 2011, 76 (09) : A319 - A320
[49] Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study
Fox, E. J.
Markowitz, C.
Applebee, A.
Montalban, X.
Wolinsky, J. S.
Belachew, S.
Fiore, D.
Han, J.
Musch, B.
Giovannoni, G.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 658 - 659
[50] Effect of ocrelizumab treatment in peripheral blood leukocyte subsets of primary progressive multiple sclerosis patients
Fernandez-Velasco, J. I.
Kuhle, J.
Monreal, E.
Meca-Lallana, V.
Meca-Lallana, J.
Izquierdo, G.
Gascon Gimenez, F.
Sainz De La Maza, S.
Walo Delgado, P.
Maceski, A.
Rodriguez-Martin, E.
Roldan, E.
Villarrubia, N.
Saiz, A.
Blanco, Y.
Sanchez, P.
Carreon Guarnizo, E.
Aladro, Y.
Brieva, L.
Iniguez, C.
Gonzalez-Suarez, I.
Rodriguez De Antonio, L.
Masjuan, J.
Costa-Frossard, L.
Villar, L. M.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 276 - 277

← 1 2 3 4 5 →